Johnson & Johnson’s (NYSE:JNJ) $14.6 billion acquisition of Intra-Cellular Therapies has gained another potential growth avenue after Caplyta met the main goal of a late-stage study in bipolar mania. J&J said Caplyta significantly reduced symptoms of bipolar mania compared with placebo in the Phase 3 trial. Patients began showing improvement as early as three days after starting treatment, with the benefits maintained through the study’s three-week duration. The study also met a key secondary goal measuring the overall severity of illness.
DON’T MISS: Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
The results could bring Caplyta a step closer to expanding beyond its existing U.S. indications, giving investors another development to watch as J&J builds on the neuroscience portfolio acquired through its purchase of Intra-Cellular Therapies last year.
Bull Case
The most important result for investors is that the trial met its primary endpoint. The study evaluated a once-daily 42-milligram dose of Caplyta in adults experiencing manic episodes associated with bipolar I disorder, and Johnson & Johnson said approximately 46% of patients treated with Caplyta achieved a clinical response, compared with approximately 21% of patients receiving placebo. The study also achieved its key secondary endpoint measuring overall severity of illness. According to J&J, improvements in mania symptoms were observed as early as three days after treatment began and were maintained throughout the three-week study.
For J&J, a successful expansion into bipolar mania could broaden the opportunity around an asset that already has approved uses in the United States. Caplyta is currently approved for depressive episodes associated with bipolar I and bipolar II disorder, as well as schizophrenia.
DON’T MISS: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
That makes the latest study particularly relevant to the investment case surrounding J&J’s acquisition of Intra-Cellular Therapies. The company paid $14.6 billion for the biotech last year as part of an effort to strengthen its neuroscience business. A potential additional use for Caplyta would broaden the clinical reach of one of the key assets acquired through that transaction. There is also a sizable patient population associated with the broader disorder. According to J&J, bipolar disorder affects an estimated 37 million people worldwide.
Bear Case
The positive Phase 3 results do not mean Caplyta is currently approved for bipolar mania. Reuters describes the use as experimental, and investors therefore should not treat the successful study as equivalent to regulatory approval.
In addition, the figure of approximately 37 million people refers to bipolar disorder worldwide rather than the number of patients who would necessarily be eligible for Caplyta for manic episodes associated with bipolar I disorder. It would be inappropriate to use the 37 million figure as Caplyta’s potential addressable market.
READ ALSO: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
The $14.6 billion acquisition price should also be kept separate from the latest clinical result. J&J bought Intra-Cellular Therapies to bolster its neuroscience business, but investors need to continue paying attention to how much of that acquisition’s financial value depends on a potential bipolar mania indication for Caplyta.
Conclusion
Caplyta’s latest Phase 3 success gives J&J another potential way to expand the drug beyond its currently approved uses. The study met both its primary endpoint and a key secondary endpoint, while Johnson & Johnson reported a clinical response in approximately 46% of Caplyta-treated patients versus approximately 21% on placebo.
For investors assessing J&J’s $14.6 billion Intra-Cellular Therapies acquisition, the result adds another positive clinical development to the Caplyta story, but there is still an important line between clinical success and commercial contribution.
Caplyta remains experimental for bipolar mania, and the next pieces investors need to look at include regulatory timelines, potential sales contributions, and the size of the addressable market, as that would help determine how much additional value bipolar mania could ultimately add to J&J’s neuroscience business.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
